TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S, Inozume T, Kawazu M, Ueno T, Nagasaki J, Tanji E, Honobe A, Ohnuma T, Kawamura T, Umeda Y, Nakamura Y, Kawasaki T, Kiniwa Y, Yamasaki O, Fukushima S, Ikehara Y, Mano H, Suzuki Y, Nishikawa H, Matsue H, Togashi Y.
Kawashima S, et al. Among authors: nakamura y.
J Immunother Cancer. 2021 Nov;9(11):e003134. doi: 10.1136/jitc-2021-003134.
J Immunother Cancer. 2021.
PMID: 34795004
Free PMC article.